The evolutionary blueprint for today's blockbuster weight-loss medications may trace back 600 million years to a humble roundworm. This discovery could reshape our understanding of metabolic regulation and point toward more sophisticated therapeutic approaches for obesity and diabetes. Researchers studying C. elegans worms uncovered a feeding control mechanism that operates through the balance of saturated versus monounsaturated fatty acids, working through cellular stress sensors in the endoplasmic reticulum. When this ancient pathway activates, it triggers a peptide-receptor system called PDF-1/PDFR-1, which induces what scientists term "food-apathy" – causing worms to leave concentrated food sources and roam rather than continue eating. The striking parallel emerges when considering that PDF-1/PDFR-1 appears to be the evolutionary ancestor of the GLP-1/GIP hormone family that powers modern medications like Ozempic and Mounjaro. To test this connection, researchers synthesized a 37-amino acid peptide derived from the worm's PDF-1 system and administered it to mice, achieving significant weight reduction and improved insulin sensitivity. This ancestral mechanism suggests that metabolic regulation through fatty acid sensing represents a fundamental biological strategy that predates complex hormone systems in mammals. The worm model offers a simpler system for understanding how cellular lipid composition directly influences feeding behavior through neuronal serotonin pathways. For human health applications, this research illuminates why GLP-1-based therapies prove so effective and suggests that targeting upstream fatty acid sensing mechanisms could yield next-generation metabolic interventions with potentially fewer side effects than current approaches.